通过脂纳米颗粒选择性氧化物再分配:一种新的策略,以减轻大量的氧化物释放,并防止在败血性休克中发生再注射损伤
Ryan Sasse1, Nathan Carpenter2, Cuthbert O Simpkins2
1University of Missouri Kansas City School of Medicine, Kansas City, MO, USA.
Free radical biology & medicine
|December 7, 2024
概括
VBI-S纳米粒子调节氧化物 (NO) 和酸盐在败血症休克中的水平,减少低血压和有毒的自由基. 这种新的疗法可以改善组织输液,并防止氧化损伤.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 氧化 (NO) 对于血管度至关重要,但在败血性休克中过度释放会导致低血压和自由基损伤.
- 目前对败血症休克的治疗方法在管理NO失调和氧化应激方面面临挑战.
研究的目的:
- 为了研究VBI-S,一种脂纳米粒子,作为治疗性冲击的治疗剂.
- 阐明VBI-S调节氧化并减轻败血症引起的损伤的机制.
主要方法:
- 由甲基胆和大豆油组成的VBI-S纳米颗粒被设计为吸收和重新分配NO和酸盐.
- 拟议的机制涉及NO/化物再分配,反应性物种清理,以及对过氧化物的保护.
主要成果:
- VBI-S捕获并重新分配NO/化物,有可能在缺氧组织中再生NO以改善 perfusion.
- VBI-S可能会抑制线粒体复合体I,减少超氧化物产生和氧化应激.
- VBI-S的脂质成分充当诱目标,保护细胞膜免受过氧酸盐损伤.
结论:
- VBI-S在调节NO和减轻低血压和败血性休克中氧化损伤方面显示出有前途.
- 需要进一步的研究来确认分子途径,并优化VBI-S.的临床应用.
相关概念视频
Nitric Oxide Signaling Pathway
4.9K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
4.9K
Antihypertensive Drugs: Vasodilators
476
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
476
Antianginal Drugs: Nitrates and β-Blockers
520
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
520
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
129
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
129
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
147
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
147
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K


